Modified neurotoxin derived from Naja genus snake venom
OwnerMurray J. Sandersinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition, a process of production thereof, and a method for treatment of neurological diseases, and especially to the treatment of such diseases as amyotropic lateral sclerosis, by administering detoxified but neurotropically active modified snake venom neurotoxin composition derived from the venom of the Naja genus, where the composition exhibits at least a 30% inhibition of viral plaques in the Semliki Forest virus test and a bioassay shows the composition to be atoxic.
Claims14
A method of treatment of animals suffering from a progressive degenerative neurological disease of motor nerve cell origins to neuromuscular junction, axones and nerve myelin sheaths comprising administering to the animal a disease mitigating amount of a detoxified and neurotropically active modified snake venom neurotoxin composition wherein the said snake venom neurotoxin is derived from the venom of a species of the Naja genus, and wherein said composition exhibits at least a 30% inhibition of plaques in the Semliki Forest virus test and a bioassay shows that the composition is atoxic, as demonstrated by essentially no signs of toxicity in inoculated laboratory animals and in the Semliki Forest virus test.
A composition comprising an administrable form of a detoxified and neurotropically active modified snake venom neurotoxin wherein the said snake venom neurotoxin is derived from the venom of a species of the Naja genus, and wherein the composition exhibits at least a 30% inhibition of plaques in the Semliki Forest virus test and a bioassay shows that the composition is atoxic, as demonstrated by essentially no signs of toxicity in inoculated laboratory animals and in the Semliki Forest virus test.
Dependencies are inferred from the claim text.